{"abstract":"This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to HUIYU Pharmaceuticals Co, Ltd located in Neijiang City, CHINA to practice the inventions embodied in U.S. Provisional Patent Application 61/833,732, filed June 11, 2013 entitled \"Her2-Specific Monoclonal Antibodies and Conjugates Thereof\" [HHS Ref. No.: E-351- 2013/0-US-01], and International Application PCT/US2014/041492, filed June 9, 2014 entitled \"Her2-Specific Monoclonal Antibodies and Conjugates Thereof\" [HHS Ref. No.: E-351-2013/0-PCT-02], any PCT, US or foreign applications claiming the benefit of. The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective exclusive license territory may be limited to China, and the field of use may be limited to:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2015/01/06/2014-30878.html","cfr_references":[],"citation":"80 FR 510","comment_url":null,"comments_close_on":"2015-02-05","correction_of":null,"corrections":[],"dates":"Only written comments or applications for a license (or both) which are received by the NIH Office of Technology Transfer on or before February 5, 2015 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[{"supporting_documents":[],"agency_name":"NIH","documents":[{"comment_count":0,"comment_start_date":"2015-01-06","updated_at":"2023-02-28T17:10:57.804-05:00","comment_url":"https://www.regulations.gov/commenton/NIH_FRDOC_0001-10297","allow_late_comments":null,"id":"NIH_FRDOC_0001-10297","comment_end_date":"2015-02-06","regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"NIH_FRDOC_0001","title":"Recently Posted NIH Rules and Notices."}],"document_number":"2014-30878","effective_on":null,"end_page":510,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2015/01/06/2014-30878.xml","html_url":"https://www.federalregister.gov/documents/2015/01/06/2014-30878/prospective-grant-of-exclusive-license-her2-monoclonal-antibodies-antibody-drug-conjugates-and-site","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2014-30878?publication_date=2015-01-06","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2015-01-06/2014-30878/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":194,"last_updated":"2026-09-23 00:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2015-01-06/pdf/2014-30878.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2014-30878.pdf?1420465755","publication_date":"2015-01-06","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2015/01/06/2014-30878.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":0,"agency_id":"NIH","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","document_id":"NIH_FRDOC_0001-10297","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2023-02-28T22:10:56Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":510,"subtype":null,"title":"Prospective Grant of Exclusive License: Her2 Monoclonal Antibodies, Antibody Drug Conjugates, and Site Specific Antibody Conjugate Methods for the Treatment of Cancer","toc_doc":"Her2 Monoclonal Antibodies, Antibody Drug Conjugates, and Site Specific Antibody Conjugate Methods for the Treatment of Cancer","toc_subject":"Exclusive Licenses:","topics":[],"type":"Notice","volume":80}